Compare Novartis AG (NVS) vs Tesla, Inc. (TSLA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Tesla, Inc. — how do they compare? Novartis AG trades at $142.04 (market cap $274.00B), while Tesla, Inc. trades at $379.45 (market cap $1.49T). The key difference: Tesla, Inc. is far larger — about 5.4× Novartis AG's market cap, and Novartis AG pays a 3.31% dividend while Tesla, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Tesla, Inc. for 88 Days on average.
| NVS | TSLA | |
|---|---|---|
Market Cap | $274.00B | $1.49T |
Volume | 1,852,137 | 25,496,215 |
Sector | Health | Consumer Cyclical |
52-Week High | $168.62 | $489.88 |
52-Week Low | $121.80 | $298.16 |
Typical Hold Time | 82 Days | 88 Days |
Enterprise Value | $315.32B | $1.46T |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.11, up 1.65% with mixed technical signals showing neutral momentum. The company maintains strong profitability with 22.5% net margins and recently announced a $7.8B licensing deal with China's Abogen. Recent earnings show two beats and one miss in the last three quarters, with Q3 2026 results pending. The stock trades below the consensus price target of $146, suggesting modest upside potential from current levels.
Novartis presents a balanced investment case with strong cash flow generation and profitability offset by recent clinical setbacks and M&A scrutiny. The $7.8B Abogen partnership expands the autoimmune pipeline, but investors face risks from patent cliffs and drug development failures. Analyst consensus leans cautious with 68% hold ratings, reflecting uncertainty around pipeline execution amid ongoing strategic repositioning.
Tesla (TSLA) trades at $375.03, down 1.48% with a mixed technical picture showing bullish moving averages but neutral oscillators. The company reported Q2 2026 earnings miss ($0.33 actual vs $0.50 expected) following two previous beats, with revenue declining to $94.83B in 2025. Analyst sentiment remains divided with 41% buy ratings but a consensus price target of $441.36 suggesting 18% upside. Recent regulatory approval for driver-assistance software in Europe provides near-term catalyst potential.
Tesla faces execution risks amid slowing auto growth but maintains leadership in autonomous driving technology. The stock's premium valuation (P/E 349.82) requires successful expansion into robotics and AI to justify current levels. Near-term pressure from delivery misses contrasts with long-term potential in energy and autonomy markets, creating a high-risk, high-reward investment profile.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Tesla, Inc.
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →
